Overview

Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain

Status:
Completed
Trial end date:
2012-06-18
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate the safety and tolerability of COV795 with up to 35 days use as evaluated by physical exam, vital signs, pulse oximetry, clinical laboratory tests, and other adverse events (AEs).
Phase:
Phase 3
Details
Lead Sponsor:
Mallinckrodt